Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond
- PMID: 24993587
- DOI: 10.1179/1607845414Y.0000000175
Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond
Abstract
Objectives: Myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT) with a matched sibling donor (MSD) in first complete remission (CR1) is an effective consolidation for adult acute lymphoblastic leukemia (ALL), and matched unrelated donor (MUD) is an alternative stem cell source.
Methods: Based on a search of the English literature for MUD transplant in Philadelphia-negative ALL, this review first compares the treatment outcomes of myeloablative allo-HSCT with MUD and MSD, followed by a mini-review of studies of non-myeloablative, reduced intensity conditioning (RIC) allo-HSCT in ALL, and finally measures to improve outcome of MUD allo-HSCT.
Results: Publications are inevitably confounded by inclusion of Philadelphia-positive cases, patients beyond CR1, and mismatched unrelated donors in addition to heterogeneity in the length of follow-up. Despite these limitations, the overall data showed that MUD allo-HSCT resulted in comparable survivals with matched related donor (MRD) transplant. Moreover, Asian studies reported a lower transplant-related mortality (TRM) than Western studies. As graft failure is infrequent even in the MUD setting, acute graft versus host disease (aGVHD) remains a major cause of TRM. In addition, RIC allo-HSCT produced promising long-term disease-free survival (DFS) with a low TRM in adult ALL if transplanted in CR1.
Discussion: Potential ways to reduce TRM further include antifungal prophylaxis and optimal management of life-threatening non-infective interstitial pneumonitis. Moreover, harnessing graft-versus-leukemia effect with hypomethylating agents warrants clinical trial.
Conclusion: Myeloablative MUD allo-HSCT resulted in comparable survivals with MRD transplant. RIC allo-HSCT produced promising long-term DFS with a low TRM in adult ALL.
Keywords: Acute lymphoblastic leukemia; Allogeneic; Matched unrelated donor; Myeloablative; Reduced intensity conditioning.
Similar articles
-
Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia.Biol Blood Marrow Transplant. 2015 Jun;21(6):1110-6. doi: 10.1016/j.bbmt.2015.02.009. Epub 2015 Feb 16. Biol Blood Marrow Transplant. 2015. PMID: 25698612
-
Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.Ann Hematol. 2021 Jun;100(6):1579-1591. doi: 10.1007/s00277-020-04355-1. Epub 2020 Nov 24. Ann Hematol. 2021. PMID: 33236196
-
Effect of graft source on unrelated donor hemopoietic stem cell transplantation in adults with acute myeloid leukemia after reduced-intensity or nonmyeloablative conditioning: a study from the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire.Biol Blood Marrow Transplant. 2015 Jun;21(6):1059-67. doi: 10.1016/j.bbmt.2015.02.014. Epub 2015 Feb 20. Biol Blood Marrow Transplant. 2015. PMID: 25708220
-
Hematopoietic stem cell transplant in adults with acute lymphoblastic leukemia: the present state.Expert Rev Hematol. 2018 Mar;11(3):195-207. doi: 10.1080/17474086.2018.1433030. Epub 2018 Feb 7. Expert Rev Hematol. 2018. PMID: 29376437 Review.
-
Hematopoietic Stem Cell Transplantation for Adult Philadelphia-Negative Acute Lymphoblastic Leukemia in the First Complete Remission in the Era of Minimal Residual Disease.Curr Oncol Rep. 2018 Mar 26;20(4):36. doi: 10.1007/s11912-018-0679-9. Curr Oncol Rep. 2018. PMID: 29577208 Review.
Cited by
-
Long-Term Results of Hematopoietic Cell Transplantation (HCT) for Adults with Blood Disorders- A Systematic Review.Stem Cell Rev Rep. 2025 Aug;21(6):1611-1630. doi: 10.1007/s12015-025-10912-w. Epub 2025 Jun 18. Stem Cell Rev Rep. 2025. PMID: 40531405 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials